Promising cancer drug falls short in rare tumor trial
NCT ID NCT04042714
First seen Nov 05, 2025 · Last updated May 20, 2026 · Updated 25 times
Summary
This study tested the drug TAS-102 (also known as Lonsurf) in 14 people with a rare and aggressive type of neuroendocrine cancer that started outside the lungs. The goal was to see if the drug could shrink tumors or improve survival. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor Scott and White University Medical Center,
Dallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.